Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis

Urologic Oncology: Seminars and Original Investigations

Volumn 24, Issue 1, 2006, Pages 4-12

  Saad, Fred ^a   McKiernan, James ^b   Eastham, James ^c  

^a NOTRE DAME HOSPITAL   (Canada)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Bisphosphonates; Bone loss; Bone metastases; Hormone sensitive; Prostate cancer

Indexed keywords

ANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; MITOXANTRONE; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PARACETAMOL; PLACEBO; PREDNISONE; ZOLEDRONIC ACID;

ARTICLE; BONE DENSITY; BONE METASTASIS; BONE NECROSIS; BONE PAIN; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DISEASE COURSE; DRUG MECHANISM; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; MYALGIA; NAUSEA; NONHUMAN; OSTEOLYSIS; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; PROSTATE CANCER; SPINAL CORD COMPRESSION; VOMITING;

ALGORITHMS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; HUMANS; IMIDAZOLES; MALE; MORBIDITY; OSTEOCLASTS; PROSTATIC NEOPLASMS;

EID: 30744463509     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2005.06.020     Document Type: Article

References (57)

1. J. Ferlay, F. Bray, P. Pisani GLOBOCAN 2000: Cancer incidence, mortality and prevalence worldwide, version 1.0. IARC Cancer Base No. 5 2001 IARC Press Lyon Available at: http://www-dep.iarc.fr/globocan/cdrom.htm. Accessed June 9, 2004.
2. A. Jemal, R.C. Tiwari, T. Murray Cancer statistics, 2004 CA Cancer J Clin 54 2004 8 29
3. H. Zincke, E.J. Bergstralh, M.L. Blute Radical prostatectomy for clinically localized prostate cancer Long-term results of 1,143 patients from a single institution J Clin Oncol 12 1994 2254 2263
4. H. Zincke, J.E. Oesterling, M.L. Blute Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer J Urol 152 1994 1850 1857
5. R.E. Coleman Metastatic bone disease Clinical features, pathophysiology and treatment strategies Cancer Treat Rev 27 2001 165 176
6. E.D. Crawford Skeletal complications in men with prostate cancer Effects on quality-of-life outcomes throughout the continuum of care Eur Urol 3 Suppl 2004 10 15
7. N.A. Siddiqui, K.R. Shetty, E.H. Duthie Osteoporosis in older men Discovering when and how to treat it Geriatrics 54 1999 20 22
8. J. Morote, E. Martinez, E. Trilla Osteoporosis during continuous androgen deprivation Influence of the modality and length of treatment Eur Urol 44 2003 661 665
9. J.T. Wei, M. Gross, C.A. Jaffe Androgen deprivation therapy for prostate cancer results in significant loss of bone density Urology 54 1999 607 611
10. S.A. Hussain, R. Weston, R.N. Stephenson Immediate dual energy X-ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation BJU Int 92 2003 690 694
11. M.R. Smith, F.J. McGovern, M.A. Fallon Low bone mineral density in hormone-naive men with prostate carcinoma Cancer 91 2001 2238 2245
12. J. Pfeilschifter, I.J. Diel Osteoporosis due to cancer treatment Pathogenesis and management J Clin Oncol 18 2000 1570 1593
13. S. Modi, L. Wood, K. Siminoski A comparison of the prevalence of osteoporosis and vertebral fractures in men with prostate cancer on various androgen deprivation therapies Preliminary report Proc Am Soc Clin Oncol 20 2001 167b [Abstract 2420].
14. M.D. Michaelson, R.M. Marujo, M.R. Smith Contribution of androgen deprivation therapy to elevated osteoclast activity in men with metastatic prostate cancer Clin Cancer Res 10 2004 2705 2708
15. E. Mazeman, P. Bertrand Early versus delayed hormonal therapy in advanced prostate cancer Eur Urol 30 Suppl 1 1996 40 43
16. A.K. David, R. Khwaja, G.R. Hudes Treatments for improving survival of patients with prostate cancer Drugs Aging 20 2003 683 699
17. E.M. Messing, J. Manola, M. Sarosdy Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer N Engl J Med 341 1999 1781 1788
18. A. Berruti, L. Dogliotti, M. Tucci Metabolic bone disease induced by prostate cancer Rationale for the use of bisphosphonates J Urol 166 2001 2023 2031
19. L.M. Demers, L. Costa, A. Lipton Biochemical markers and skeletal metastases [special issue] Clin Orthop Relat Res Suppl 415 2003 S138 S147
20. F. Saad, D.M. Gleason, R. Murray Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer J Natl Cancer Inst 96 2004 879 882
21. F. Saad, R.M. Bukowski, A. Lipton Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to prostate and renal cancer 2003 [abstract], Presented at: 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 31-June 3. Available at: http://www.asco.org. Accessed January 14, 2004.
22. G. Poor, E.J. Atkinson, D.G. Lewallen Age-related hip fractures in men Clinical spectrum and short-term outcomes Osteoporos Int 5 1995 419 426
23. T.H. Diamond, C.S. Higano, M.R. Smith Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy recommendations for diagnosis and therapies Cancer 100 2004 892 899
24. M. Cree, C.L. Soskolne, E. Belseck Mortality and institutionalization following hip fracture J Am Geriatr Soc 48 2000 283 288
25. M.G. Oefelein, V. Ricchiuti, W. Conrad Skeletal fractures negatively correlate with overall survival in men with prostate cancer J Urol 168 2002 1005 1007
26. A. Lipton Management of metastatic bone disease and hypercalcemia of malignancy Am J Cancer 2 2003 427 438
27. M.R. Smith, J. Eastham, D.M. Gleason Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer J Urol 169 2003 2008 2012
28. F. Saad, D.M. Gleason, R. Murray A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma J Natl Cancer Inst 94 2002 1458 1468
29. D.S. Ernst, I.F. Tannock, E.W. Winquist Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain J Clin Oncol 21 2003 3335 3342
30. D.P. Dearnaley, M.R. Sydes, M.D. Mason MRC PR05. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial) J Natl Cancer Inst 95 2003 1300 1311
31. E.J. Small, M.R. Smith, J.J. Seaman Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer J Clin Oncol 21 2003 4277 4284
32. F. Saad, D. Gleason, R. Murray Zoledronic acid is well tolerated for up to 24 months and significantly reduces skeletal complications in patients with advanced prostate cancer metastatic to bone 2003 [poster], Poster presented at: American Urological Association 98th Annual Meeting, Chicago, IL, April 26-May 1, [Abstract 1472].
33. F. Saad, D. Gleason, R. Murray Long-term reduction of bone pain with zoledronic acid in patients with advanced prostate cancer metastatic to bone 2003 [poster], Poster presented at: American Urological Association 98th Annual Meeting, Chicago, IL, April 26-May [Abstract 1473].
34. M.R. Smith, F.J. McGovern, A.L. Zietman Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer N Engl J Med 345 2001 948 955
35. ZOMETA® [package insert] 2005 Novartis Pharmaceuticals Corp East Hanover, NJ
36. R.E. Marx Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws A growing epidemic J Oral Maxillofac Surg 61 2003 1115 1117
37. J. Wang, N.M. Goodger, M.A. Pogrel Osteonecrosis of the jaws associated with cancer chemotherapy J Oral Maxillofac Surg 61 2003 1104 1107
38. M.A. Pogrel Bisphosphonates and bone necrosis J Oral Maxillofac Surg 62 2004 391 392
39. C.A. Migliorati Bisphosphonates and oral cavity avascular bone necrosis J Clin Oncol 21 2003 4253 4254
40. G.D. Carter, A.N. Goss Bisphosphonates and avascular necrosis of the jaws Aust Dent J 48 2003 268
41. S.L. Ruggiero, B. Mehrotra, T.J. Rosenberg Osteonecrosis of the jaws associated with the use of bisphosphonates A review of 63 cases J Oral Maxillofac Surg 62 2004 527 534
42. J.M. McKiernan, T.E. Delea, M. Liss Impact of skeletal complications on total medical care costs in prostate cancer patients with bone metastases Proc Am Soc Clin Oncol 23 2004 531 [Abstract 6057].
43. M.T. Groot, C.G. Boeken Kruger, R.C. Pelger Costs of prostate cancer, metastatic to the bone, in the Netherlands Eur Urol 43 2003 226 232
44. T.L. Krupski, M.R. Smith, W.C. Lee Profile of men with prostate cancer on androgen deprivation therapy at greatest risk of bone complications Proc Am Soc Clin Oncol 22 Suppl 2004 726 [Abstract 8000].
45. M.R. Smith, W.C. Lee, T. Krupsi Association between androgen deprivation therapy and fracture risk A population-based cohort study in men with non-metastatic prostate cancer Proc Am Soc Clin Oncol 22 2004 383 [Abstract 4507].
46. S.S. Padalecki, M. Carreon, B. Grubbs Androgen deprivation enhances bone loss and prostate cancer metastases to bone Prevention by zoledronic acid Oncology 17 Suppl 3 2003 32
47. C.T. McMurtry, J.M. McMurtry Metastatic prostate cancer Complications and treatment J Am Geriatr Soc 51 2003 1136 1142
48. J.R. Berenson, A. Lichtenstein, L. Porter Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events J Clin Oncol 16 1998 593 602
49. K.P. Weinfurt, Y. Li, L.D. Castel The impact of skeletal-related events on health-related quality of life of patients with metastatic prostate cancer Ann Oncol 13 Suppl 5 2002 180 [Abstract 662P].
50. L.S. Rosen, D. Gordon, M. Kaminski Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma A randomized, double-blind, multicenter, comparative trial Cancer 98 2003 1735 1744
51. L.S. Rosen, D. Gordon, S. Tchekmedyian Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors A phase III, double-blind, randomized trial - The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group J Clin Oncol 21 2003 3150 3157
52. M.H. Cohen, R. Dagher, D.J. Griebel U.S. Food and Drug Administration drug approval summaries Imatinib mesylate, mesna tablets, and zoledronic acid Oncologist 7 2002 393 400
53. P.R. Carroll, D. Neal, H. Scher Management of disseminated prostate cancer L. Denis G. Bartsch S. Khoury Prostate cancer 3rd International Consultation on Prostate Cancer-Paris 2003 Health Publications Paris, France 251 284
54. World Health Organization Assessment of fracture risk and its application to screening for post-menopausal osteoporosis 1994 WHO Geneva, Switzerland Technical report series, No. 843.
55. C.S. Higano Management of bone loss in men with prostate cancer J Urol 170 2003 S59 S63
56. L.S. Rosen, D. Gordon, N.S. Tchekmedyian Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors A randomized, phase III, double-blind, placebo-controlled trial Cancer 100 2004 2613 2621
57. S.M. Ali, F.J. Esteva, G. Hortobagyi Safety and efficacy of bisphosphonates beyond 24 months in cancer patients J Clin Oncol 19 2001 3434 3437